Fertility Medications: Uses, Types, and Safety Considerations

How fertility medications work

The reproductive system is controlled by a hormone feedback loop involving the hypothalamus, pituitary gland, ovaries, and, when pregnancy occurs, the developing placenta.

The hypothalamus releases gonadotropin-releasing hormone (GnRH). This signals the pituitary gland to release follicle-stimulating hormone (FSH) and luteinising hormone (LH). FSH helps ovarian follicles grow. LH helps trigger ovulation and supports hormone changes around the time an egg is released.

Fertility medications work by influencing this hormone system in different ways. Some medicines encourage the body to produce more FSH and LH naturally. Some provide FSH or LH activity directly. Some control the timing of ovulation. Others support the uterine lining after ovulation or embryo transfer.

Because these medicines affect hormone pathways, they require careful medical supervision. Response can vary significantly between patients.

Main categories of fertility medications

Fertility medicines are usually grouped by their role in a treatment cycle.

Common groups include:

• ovulation induction medicines;
• injectable gonadotropins;
• medicines used to trigger final egg maturation;
• medicines used to prevent premature ovulation during IVF;
• luteal phase support medicines;
• adjunct medicines for specific hormone-related causes of infertility.

These categories are not interchangeable. A medicine used for ovulation induction is not the same as a medicine used for luteal support. A medicine used in an IVF cycle may not be appropriate for a simpler ovulation induction cycle.

Ovulation induction medicines

Ovulation induction medicines are commonly used when ovulation is irregular or absent. They may be used in conditions such as polycystic ovary syndrome (PCOS) or other forms of ovulatory dysfunction, depending on the clinical assessment.

Clomifene

Clomifene, also known as clomiphene in some countries, is a selective estrogen receptor modulator. It acts mainly by reducing estrogen feedback at the level of the hypothalamus and pituitary gland. This can increase the body’s own release of FSH and LH, which may help stimulate follicle development and ovulation.

Clomifene is usually considered only after evaluation of the likely cause of ovulatory dysfunction. It is not suitable for every patient. Medical assessment is needed to exclude or manage other factors that may prevent pregnancy, such as ovarian cysts, abnormal uterine bleeding, liver disease, pregnancy, primary ovarian insufficiency, tubal factors, or sperm-related factors.

Clomifene can increase the chance of multiple ovulation and therefore may increase the risk of multiple pregnancy. Monitoring practices vary by clinic and country.

Aromatase inhibitors

Aromatase inhibitors, such as letrozole, may be used in some fertility settings to support ovulation. In many countries this use may be off-label, meaning the medicine is being used outside its original approved indication or outside the exact wording of its product licence.

Aromatase inhibitors temporarily reduce estrogen production. This can lead to increased pituitary release of FSH, which may support follicle growth.

Whether an aromatase inhibitor is appropriate depends on diagnosis, local clinical guidelines, patient characteristics, and specialist judgement.

Gonadotropins

Gonadotropins are injectable medicines that provide FSH activity, LH activity, or both. They act directly on the ovaries to stimulate follicle development.

They are used in different fertility settings, including ovulation induction, IUI cycles, and controlled ovarian stimulation for IVF. They are usually monitored with ultrasound scans and blood hormone tests because the ovarian response can be too low, appropriate, or excessive.

Menotrophin

Menotrophin, also called human menopausal gonadotropin or hMG, contains FSH and LH activity. It is traditionally derived from the urine of postmenopausal donors and then purified for medical use.

Menotrophin is used to stimulate ovarian follicle development. Because it can stimulate more than one follicle, monitoring is important to reduce the risk of excessive ovarian response, ovarian hyperstimulation syndrome, and multiple pregnancy.

Recombinant FSH and recombinant LH

Recombinant gonadotropins are produced using biotechnology rather than extracted from urine. Recombinant FSH provides follicle-stimulating hormone activity and is commonly used in controlled ovarian stimulation. Recombinant LH may be used in selected situations where LH activity is needed.

These medicines allow precise dosing, but precise dosing does not remove risk. Follicle number, estradiol levels, ovarian reserve, PCOS status, age, and previous response to treatment can all affect safety and outcome.

Trigger medicines

A trigger medicine is used to support the final maturation of eggs and control the timing of ovulation or egg retrieval.

Human chorionic gonadotropin

Human chorionic gonadotropin, often abbreviated as hCG, acts in a similar way to LH. It may be used as a trigger injection before timed intercourse, IUI, or egg retrieval in IVF.

Timing is critical. In an IVF cycle, egg retrieval is scheduled around the expected response to the trigger. Incorrect timing can affect the cycle. Patients should follow the clinic’s instructions exactly and contact the clinic if a trigger dose is missed, delayed, or taken incorrectly.

hCG can contribute to the risk of ovarian hyperstimulation syndrome in susceptible patients. Clinics may use different trigger strategies depending on OHSS risk.

GnRH agonist trigger

In some IVF protocols, especially GnRH antagonist cycles, a GnRH agonist trigger may be used instead of hCG or as part of a dual-trigger approach. This choice depends on the protocol, the patient’s response, and the clinic’s risk assessment.

Trigger selection should be made by the fertility specialist. It is not a decision that should be copied from another patient’s cycle.

Medicines that control premature ovulation

During IVF, clinics may use medicines to prevent the body from releasing eggs before retrieval.

GnRH antagonists

GnRH antagonists rapidly reduce pituitary LH release and help prevent a premature LH surge. They are commonly used in controlled ovarian stimulation protocols.

They may be preferred in some patients at increased risk of ovarian hyperstimulation syndrome, but the choice of protocol depends on the full clinical picture.

GnRH agonists

GnRH agonists can also be used to control ovarian stimulation cycles. Their effect depends on timing and duration of use. They may initially stimulate hormone release and then suppress pituitary hormone production after continued use.

GnRH agonist protocols are still used in some clinical situations. They require careful scheduling and patient instruction.

Luteal phase support

After ovulation, egg retrieval, or embryo transfer, the body may need support during the luteal phase. The luteal phase is the part of the cycle after ovulation, when the uterine lining should remain receptive.

Progesterone

Progesterone helps prepare and maintain the endometrium, the lining of the uterus. It may be used after ovulation induction, IUI, IVF, or embryo transfer depending on the protocol.

Progesterone can be supplied in different forms, including vaginal capsules, pessaries, gels, tablets, injections, or oral formulations depending on the country and product. These forms are not automatically equivalent. Patients should use the exact form and schedule prescribed by their clinic.

Adjunct medicines in fertility care

Some patients may need treatment for a specific hormone or metabolic issue that affects fertility.

Examples include:

• medicines that reduce high prolactin levels, such as cabergoline or bromocriptine;
• thyroid medicines when thyroid disease is affecting reproductive health;
• insulin-sensitising treatment in selected patients with PCOS or metabolic concerns;
• medicines used as part of endometriosis, fibroid, or hormone-suppression protocols;
• supportive medicines used in specialist IVF protocols.

Adjunct medicines should not be added without medical advice. Their role depends on diagnosis and test results.

Common medical uses

Fertility medications may be used for several different treatment goals.

Ovulatory dysfunction

Ovulatory dysfunction means ovulation is irregular or absent. Medicines such as clomifene, aromatase inhibitors, or gonadotropins may be considered depending on the diagnosis and local practice.

PCOS is one common cause of ovulatory dysfunction, but it is not the only cause. Thyroid disease, high prolactin, low body weight, stress, premature ovarian insufficiency, and other endocrine problems may also affect ovulation.

Assisted reproductive technology

In IVF, injectable medicines are often used to stimulate the ovaries to develop multiple follicles. The aim is to retrieve eggs for fertilisation in a laboratory.

This process is called controlled ovarian stimulation. It requires close monitoring because too little response may reduce the chance of retrieving eggs, while excessive response can increase the risk of complications.

IUI and timed intercourse cycles

Some patients use fertility medicines with timed intercourse or intrauterine insemination. In these cycles, the goal may be to support the development of one or a small number of follicles.

Monitoring is still important because producing too many follicles can increase the risk of multiple pregnancy.

Luteal phase support

Progesterone may be used when luteal support is needed after ovulation, egg retrieval, or embryo transfer. This is especially common in IVF protocols.

The need for luteal support depends on the treatment type and clinic protocol.

Why monitoring matters

Fertility medicines can produce different responses in different patients. Two patients taking the same medicine may have very different follicle growth, hormone levels, side effects, and risks.

Monitoring may include:

• transvaginal ultrasound to count and measure follicles;
• blood tests, including estradiol and sometimes LH or progesterone;
• review of symptoms;
• adjustment of medicine dose;
• cancellation or conversion of a cycle if the response is unsafe.

Monitoring is not only about improving pregnancy chances. It is also a safety measure.

Ovarian hyperstimulation syndrome

Ovarian hyperstimulation syndrome, or OHSS, is an excessive response to ovarian stimulation. It is most commonly associated with injectable gonadotropins, although risk varies by patient and protocol.

OHSS can cause enlarged ovaries, abdominal bloating, pain, nausea, vomiting, rapid weight gain, and fluid shifts. Severe OHSS can involve dehydration, blood clot risk, kidney problems, fluid in the abdomen or chest, and hospital care.

Patients should contact their clinic urgently if they develop concerning symptoms after fertility treatment, especially severe abdominal pain, breathing difficulty, faintness, rapid weight gain, reduced urination, persistent vomiting, or significant abdominal swelling.

Clinics reduce OHSS risk by individualising treatment, adjusting doses, monitoring follicle growth and hormone levels, changing trigger strategy, freezing embryos instead of doing a fresh transfer, or cancelling a cycle when needed.

Multiple pregnancy

Fertility medicines can increase the chance that more than one egg is released or more than one embryo implants. This can lead to twin, triplet, or higher-order pregnancy.

Multiple pregnancy carries higher risks for the pregnant patient and babies, including miscarriage, preterm birth, high blood pressure, gestational diabetes, growth restriction, and neonatal complications.

This is one reason fertility treatment should be monitored. More follicles do not always mean a safer or better outcome.

Side effects and practical considerations

Side effects vary by medicine and individual response.

Possible side effects may include:

• hot flushes;
• mood changes;
• breast tenderness;
• headaches;
• abdominal bloating;
• pelvic discomfort;
• nausea;
• injection-site reactions;
• visual symptoms with some medicines;
• ovarian cysts or ovarian enlargement;
• emotional stress related to treatment.

Patients should report side effects to their healthcare team, especially severe symptoms, visual changes, heavy bleeding, allergic reactions, or symptoms suggestive of OHSS.

Fertility treatment can also be emotionally difficult. Repeated tests, injections, cycle uncertainty, cost, and waiting periods can affect mental wellbeing. Psychological support, counselling, or patient support groups may be useful for some people.

Country-specific regulation and medical authorities

Fertility medicines are regulated differently across countries.

In the United States, medicines are regulated by the FDA. In the European Union, medicines may be assessed through the European Medicines Agency and national medicines authorities. In the United Kingdom, medicines are regulated by the MHRA, while fertility clinics are also overseen by the HFEA. In Australia, medicines are regulated by the TGA. In New Zealand, medicines are regulated by Medsafe. Other countries have their own national authorities.

These authorities may use similar scientific concepts, such as active ingredient, dosage form, strength, quality standards, safety data, and approved indications. However, product names, approved uses, available strengths, patient leaflets, prescription status, import rules, and clinic protocols may differ.

A medicine used in fertility care in one country may be unavailable, differently labelled, differently licensed, or used off-label in another country. Patients should follow the rules and medical advice that apply in their own location.

Working with a healthcare team

Fertility medication should be managed by a qualified healthcare professional, usually a fertility specialist, reproductive endocrinologist, gynaecologist, or clinic team.

Before treatment, assessment may include:

• medical and reproductive history;
• menstrual cycle history;
• ultrasound evaluation;
• ovarian reserve testing;
• hormone testing;
• semen analysis where relevant;
• screening for tubal, uterine, endocrine, or genetic factors;
• review of current medicines and allergies.

During treatment, the plan may be adjusted based on response. Patients should not change dose, timing, route, or medicine type without clinical instruction.

What should patients take away?

Fertility medications can support ovulation, controlled ovarian stimulation, egg maturation, embryo transfer preparation, and luteal phase support. They are important tools in reproductive medicine, but they are not simple consumer products.

The same medicine may be used differently depending on diagnosis, treatment type, country, and clinic protocol. Similar-sounding medicines may have different roles. Different forms and strengths are not automatically interchangeable.

The safest way to understand fertility medication listings is to check the active ingredient, dosage form, strength, route, intended use, and need for monitoring. Treatment decisions should always be made with a qualified healthcare professional.

Disclaimer: This article is for general information only and does not replace medical advice, diagnosis, or treatment. Medicine suitability, dosing, monitoring, and legal status can vary by person and country. A qualified healthcare professional should be consulted before starting, stopping, or changing treatment. Fertility medicines often require clinic-specific protocols, ultrasound or blood-test monitoring, and review for OHSS and multiple-pregnancy risk.